Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)

국내 염증성장질환의 약물치료 및 약제비 현황: 2010-2014 국민건강보험자료 활용 연구

  • Ha, Jung Eun (College of Pharmacy, CHA University) ;
  • Jang, Eun Jin (College of Natural Sciences, Andong National University) ;
  • Im, Seul Gi (College of Natural Sciences, Kyungpook National University) ;
  • Sohn, Hyun Soon (College of Pharmacy, CHA University)
  • 하정은 (차의과학대학교 약학대학) ;
  • 장은진 (안동대학교 자연과학대학) ;
  • 임슬기 (경북대학교 자연과학대학) ;
  • 손현순 (차의과학대학교 약학대학)
  • Received : 2018.07.20
  • Accepted : 2018.10.04
  • Published : 2019.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Backgrounds: Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD) increased prevalence and economic burden. Objectives: This study aimed to investigate drug use pattern in IBD patients in a real world. Methods: National Health Insurance claim data from 2010 to 2014 were used in this population-based study. All IBD patients diagnosed during study period were enrolled. IBD medications included 5-aminosalicylic acid (ASA), glucocorticoid, immunomodulator and anti-tumor necrosis factor-${\alpha}$ agent(anti TNF-${\alpha}$). Growth rate of IBD prevalence, prescribed drug classes, duration of drug therapy and medication cost were analyzed. Number and percentage of patients for categorical variables, and mean and median for continuous variables were presented. Results: Total numbers of patients were 131,158 and 57,286 during 5 years, and their annual growth rate were 3.2 and 5.7% for UC and CD. UC and CD were prevalent in the 40-50 (41.2%) and 20-30 age groups (36.0%). About 60% of IBD patients was prescribed any of medications. 5-ASA was the most frequently prescribed, followed by corticosteroid and immunomodulator. Anti TNF-${\alpha}$ use was the lowest, but 5 times higher than UC in CD. Combination therapies with different class of drugs were in 29% for UC and 62% for CD. Mean prescription days per patient per year were 306 and 378, and the median medication cost per patient per year was KRW 420,000 (USD 383) and KRW 830,000 (USD755), for UC and CD, respectively. Conclusions: Increasing prevalence of IBD requires further studies to contribute to achieve better clinical outcomes of drug therapy.

Keywords

References

  1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. https://doi.org/10.1097/00054725-200207000-00002
  2. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8. https://doi.org/10.1016/j.cgh.2007.09.002
  3. Ministry of Health Welfare. Standard for calculating the deductible for the applicant. MOHW Notice No. 2017-171. 2017.9.26. National Law Information Center. Available at http://www.law.go.kr. Accessed Feb 17, 2018.
  4. Kaplan GG and Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313-21. https://doi.org/10.1053/j.gastro.2016.10.020
  5. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769-78. https://doi.org/10.1016/S0140-6736(17)32448-0
  6. Vegh Z, Kurti Z, Lakatos PL. Epidemiology of inflammatory bowel disease from west to east. J Dig Dis 2017;18(2):92-8. https://doi.org/10.1111/1751-2980.12449
  7. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14(2):111-9. https://doi.org/10.5217/ir.2016.14.2.111
  8. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27(8):1266-80. https://doi.org/10.1111/j.1440-1746.2012.07150.x
  9. Wei SC, Lin MH, Tung CC, et al. A nationwide population-based study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan. BMC Gastroenterol 2013;13:166. https://doi.org/10.1186/1471-230X-13-166
  10. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 2013;145:158-65. https://doi.org/10.1053/j.gastro.2013.04.007
  11. Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol 2014;20(33):11525-37. https://doi.org/10.3748/wjg.v20.i33.11525
  12. Shin DH, Sinn DH, Kim YH, et al. Increasing incidence of inflammatory bowel disease among young men in Korea between 2003 and 2008. Dig Dis Sci 2011;56:1154-9. https://doi.org/10.1007/s10620-010-1403-2
  13. Lee KM and Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-70. https://doi.org/10.3904/kjim.2014.29.5.558
  14. Choi CH, Moon W, Kim YS, et al. IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69(1):1-28. https://doi.org/10.4166/kjg.2017.69.1.1
  15. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62. https://doi.org/10.1016/j.crohns.2009.12.002
  16. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-38. https://doi.org/10.1038/ajg.2015.233
  17. Choi CH, Kim YH, Kim YS, et al. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the management of ulcerative colitis. Korean J Gastroenterol 2012;59(2):118-40. https://doi.org/10.4166/kjg.2012.59.2.118
  18. Choi CH, Moon W, Kim YS, et al. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res 2017;15(1):7-37. https://doi.org/10.5217/ir.2017.15.1.7
  19. Ye BD, Yang SK, Shin SJ, et al. IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the management of Crohn's disease. Korean J Gastroenterol 2012;59(2):141-79. https://doi.org/10.4166/kjg.2012.59.2.141
  20. Park JJ, Yang SK, Ye BD, et al. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15(1):38-67. https://doi.org/10.5217/ir.2017.15.1.38
  21. Statistics Korea. Korean Standard Classification of Diseases (KCD)-7 code. 2016. Korean Standard Statistical Classification. Available at https://kssc.kostat.go.kr:8443/ksscNew_web/kssc/main/main.do?gubun=1#. Accessed Feb 18, 2018.
  22. Heath Insurance Review & Assessment Service. National Drug Formulary List. Available at http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000. Accessed Dec 15, 2015.
  23. Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm Bowel Dis 2015;21:623-30. https://doi.org/10.1097/MIB.0000000000000313
  24. Kim JW, Lee CK, Rhee SY, Oh CH, Shim JJ, Kim HJ. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study. J Gastroenterol Hepatol 2017 Oct 21. doi: 10.1111/jgh.14027. [Epub ahead of print]
  25. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542-9. https://doi.org/10.1002/ibd.20310
  26. Ye BD, Han DS, Youn EJ, et al. The clinical features and prognosis of Crohn's disease: a Korean multicenter nationwide cohort study In: 9th Congress of European Crohn's and Colitis Organization; 2014 Feb 20-22. Copenhagen. Vienna: ECCO, 2014;8(Suppl 1):S315.
  27. Kuo CJ, Yu KH, See LC. The trend of inflammatory bowel diseases in Taiwan: a population-based study. Dig Dis Sci 2015;60(8):2454-62. https://doi.org/10.1007/s10620-015-3630-z
  28. Park SH, Yang SK, Park SK, et al. Long-term prognosis of Crohn's disease and its temporal change between 1981 and 2012: a hospitalbased cohort study from Korea. Inflamm Bowel Dis 2014;20:488-94. https://doi.org/10.1097/01.MIB.0000441203.56196.46
  29. Moon CM, Park DI, Kim ER, et al. Clinical features and predictors of clinical outcomes in Korean patients with Crohn's disease: a Korean association for the study of intestinal diseases multicenter study. J Gastroenterol Hepatol 2014;29:74-82. https://doi.org/10.1111/jgh.12369

Cited by

  1. 건강보험 청구자료를 이용한 궤양성 대장염 치료제의 처방 양상과 전신 스테로이드 처방에 미치는 영향요인 vol.30, pp.2, 2019, https://doi.org/10.24304/kjcp.2020.30.2.102
  2. The Impact of Korean Medicine Treatment on the Incidence of Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea vol.9, pp.8, 2019, https://doi.org/10.3390/jcm9082422
  3. Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Use of the Landmark Method vol.62, pp.11, 2019, https://doi.org/10.3349/ymj.2021.62.11.997
  4. Body image, self-esteem, and quality of life in children and adolescents with inflammatory bowel disease in a tertiary hospital in South Korea vol.27, pp.2, 2019, https://doi.org/10.4094/chnr.2021.27.2.181